Clinical trials: Advanced Solid Cancer
Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma
Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors
This is a Phase 1/1b, open-label, first-in-human, dose-escalation and expansion study of CHS-388, a monoclonal antibody that targets IL-27, as a monotherapy and in combination in patients with solid tumors.
- Conditions
- Advanced Solid Tumor, Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma, Non-small Cell Lung Cancer
- Trial name
- NCT04374877
- Testing
- CHS-388, Pembrolizumab, Toripalimab
- Where
- 23 sites in United States, Singapore and 1 more
- Volunteers
- 145 people
- Sponsor
- Coherus Oncology, Inc.
KRAS P.G12C
A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation
This is a first-in-human (FIH), multicenter, open-label, dose-escalation, and dose-expansion Phase 1/2 clinical trial to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of D3S-001…
- Trial name
- NCT05410145
- Testing
- D3S-001, Pembrolizumab, Cisplatin
- Where
- 52 sites in United States, Australia and 8 more
- Volunteers
- 442 people
- Sponsor
- D3 Bio (Wuxi) Co., Ltd
Solid Tumor
ALG.APV-527 First-in-human Study
A first-in-human, multicenter, open-label, dose escalation and dose expansion phase 1 study in patients with advanced solid tumors to evaluate the safety of intravenously administered ALG.APV-527 (Short title: ALG.APV-527…
- Trial name
- NCT05934539
- Testing
- ALG.APV-527
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Aptevo Therapeutics
Advanced / Metastatic Solid Tumor
A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid Tumors
This is an open-label, dose-escalation, multi-center phase 1 study evaluating the safety, tolerability, and pharmacokinetics (PK) of SR-8541A administered orally as a monotherapy or in combination with an immune checkpoint…
- Trial name
- NCT06063681
- Testing
- SR-8541A, Immune checkpoint inhibitor (ICI)
- Where
- 3 sites in Australia
- Volunteers
- 25 people
- Sponsor
- Stingray Therapeutics
Advanced Cancer
A Study of CS1003 in Subjects With Advanced Solid Tumors
This study will evaluate the safety, tolerability, pharmacokinetic profile and treatment effect of a new drug known as CS1003 in patients with advanced tumors.
- Trial name
- NCT03475251
- Testing
- CS1003, Regorafenib
- Where
- Australia
- Volunteers
- 108 people
- Sponsor
- CStone Pharmaceuticals
Solid Tumor
A Phase 1 Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HH-101 in Patients With Advanced Solid Tumors
The goal of this study is to evaluate the safety of HH-101 antibody, administered as monotherapy to participants with advanced solid tumors.
- Trial name
- NCT07554196
- Testing
- HH-101 (0.3 mg/kg), HH-101 (1 mg/kg ), HH-101 (3 mg/kg )
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Huahui Health
Advanced Solid Tumors
Study of TQB2450 Combined With Anlotinib in Patients With Advanced Solid Tumors
TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1),which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and…
- Trial name
- NCT03897283
- Testing
- TQB2450, Anlotinib
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Solid Tumors Patients
Phase I Clinical Study to Evaluate the Safety and Efficacy of 3SC009 Monotherapy for Patients With Advanced Solid Tumors
This study includes two parts, different part has different administration frequencies of 3SC009.
- Trial name
- NCT07815002
- Testing
- 3SC009
- Volunteers
- 100 people
- Sponsor
- Shenyang Sunshine Pharmaceutical Co., LTD.
Advanced Solid Tumor
This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors
This is a first-in-human Phase 1, single-arm, open-label, multicenter, multiple-dose, dose-escalation and dose-expansion study of ABL503 to evaluate the safety, tolerability, MTD and/or RP2D, PK, immunogenicity, preliminary…
- Trial name
- NCT04762641
- Testing
- ABL503
- Where
- 8 sites in United States, South Korea
- Volunteers
- 100 people
- Sponsor
- ABL Bio, Inc.
Solid Cancer
A Phase I Study of AK138D1 in the Treatment of Advanced Solid Tumors
This is an open-label, first-in-human, Phase I clinical study aimed at evaluating the safety, tolerability, PK, immunogenicity, and preliminary antitumor efficacy of AK138D1 in subjects being treated for advanced solid tumors.
- Trial name
- NCT06730386
- Testing
- AK138D1
- Where
- 4 sites in Australia
- Volunteers
- 100 people
- Sponsor
- Akeso
Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
This first-in-human (FIH ) study is an open-label, multicenter study that consists of a Phase 1 Dose Escalation/Expansion phase of GB1275 monotherapy or in combination with Anti-PD-1 Antibody or in combination with Standard of…
- Conditions
- Pancreatic Adenocarcinoma, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma
- Trial name
- NCT04060342
- Testing
- GB1275, nab-paclitaxel and gemcitabine, pembrolizumab
- Where
- 8 sites in United States, United Kingdom
- Volunteers
- 61 people
- Sponsor
- GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.
Advanced Solid Tumor
The Safety, Tolerability, and Initial Efficacy of HX009 in Patients With Advanced Malignancies
This is a first-in-human, multicenter, open-label, multiple-dose Phase I study to investigate the safety, tolerability, and initial efficacy of HX009 in subjects with advanced malignant tumors.
- Trial name
- NCT04097769
- Testing
- HX009
- Where
- Australia
- Volunteers
- 21 people
- Sponsor
- Waterstone Hanxbio Pty Ltd
Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and/or recommended dose for expansion (RDE) of intratumoral…
- Conditions
- Triple Negative Breast Cancer, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Lymphoma, Non-Hodgkin
- Trial name
- ON-5001 (NCT06022029)
- Testing
- ONM-501, Cemiplimab
- Where
- 16 sites in United States, Australia
- Volunteers
- 168 people
- Sponsor
- OncoNano Medicine, Inc.
Cancer
Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors
The purpose of this study is to identify a safe and tolerable dose of BMS-906024 in combination with each of the following three chemotherapy regimens: Paclitaxel, 5FU plus Irinotecan (FOLFIRI), or Carboplatin plus Paclitaxel in…
- Trial name
- NCT01653470
- Testing
- Paclitaxel, 5-Fluorouracil (5FU), Carboplatin
- Where
- 5 sites in United States, Belgium and 1 more
- Volunteers
- 141 people
- Sponsor
- Bristol-Myers Squibb
Solid Cancers
A Study of Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists
This is a single-arm, multicenter, Phase Ib study designed to describe the effect of GDC-0449 on the pharmacokinetics of rosiglitazone and oral contraceptives in patients with advanced solid tumors who are refractory to treatment…
- Trial name
- NCT01209143
- Testing
- Vismodegib, Rosiglitazone, Norethindrone/ethinyl estradiol
- Where
- 3 sites in United States
- Volunteers
- 52 people
- Sponsor
- Genentech, Inc.
Advanced Solid Tumors, Hematologic Neoplasms
A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms
The primary goal of this Phase 1 study is to characterize the safety and tolerability of tebotelimab and establish the maximum tolerated dose (MTD) of tebotelimab in advanced solid tumors, and tebotelimab in combination with…
- Conditions
- Advanced Solid Tumors, Hematologic Neoplasms, Ovarian Cancer, HER2-positive Advanced Solid Tumors
- Trial name
- NCT03219268
- Testing
- tebotelimab 1 mg, tebotelimab 3 mg, tebotelimab 10 mg
- Where
- 40 sites in United States, Australia and 6 more
- Volunteers
- 277 people
- Sponsor
- MacroGenics
Lung Cancer (Locally Advanced or Metastatic), Esophagus Cancer
A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors
This is a Phase I, first-in-human, open-label study of CRPA1A2, a bispecific T-cell engager, in participants with HLA-A*02:01-positive and MAGE-A1-positive advanced solid tumors.
- Conditions
- Lung Cancer (Locally Advanced or Metastatic), Esophagus Cancer, Head and Neck Cancer, Hepatocellular Carcinoma (HCC)
- Trial name
- NCT07583316
- Testing
- CRPA1A2
- Where
- China
- Volunteers
- 192 people
- Sponsor
- Corregene Biotechnology Co., Ltd
Advanced Solid Tumor
A Dose Escalation and Expansion Study of NB002 in Participants With Advanced or Metastatic Solid Tumors
This study is a first-in-human, multicenter, open label, uncontrolled, non-randomized, phase 1a/1b study, to evaluate the safety, tolerability, and preliminary antitumor activity of NB002 in subjects with advanced solid tumors.
- Trial name
- NCT05924906
- Testing
- NB002
- Volunteers
- 30 people
- Sponsor
- Suzhou Neologics Bioscience Co., Ltd.
Advanced Solid Tumors
First In Human, Phase 1 Study of AG013736 In Patients With Solid Tumors
The purpose of the study was to characterize the safety of investigational agent AG-013736, in patients with solid tumors in this First In Human trial.
- Trial name
- NCT01469052
- Testing
- AG-013736
- Where
- 3 sites in United States
- Volunteers
- 36 people
- Sponsor
- Pfizer
Advanced Cancer, Advanced Solid Tumor
TT-816 As Monotherapy or in Combination with a PD-1 Inhibitor in Patients with Advanced Cancers (SEABEAM) (MK3475-E88)
A first-in-human study using TT-816 as a single agent and in combination with a PD-1 inhibitor in advanced cancers.
- Conditions
- Advanced Cancer, Advanced Solid Tumor, Cancer, Oncology
- Trial name
- NCT05525455
- Testing
- TT-816, A PD-1 inhibitor
- Where
- 5 sites in United States
- Volunteers
- 9 people
- Sponsor
- Teon Therapeutics, Inc.